Identification of leukemia stem cells in acute myeloid leukemia and their clinical relevance

Acute myeloid leukemia (AML) is considered to be a disease of stem cells. A rare defective stem cell population is purported to drive tumor growth. Similarly to their normal counterparts, leukemic stem cells (LSC) divide extreme slowly. This may explain the ineffectiveness of conventional chemothera...

Full description

Saved in:
Bibliographic Details
Main Authors: Hoang, Thanh Van (Author) , Zepeda-Moreno, Abraham (Author) , Ho, Anthony Dick (Author)
Format: Article (Journal)
Language:English
Published: June 2012
In: Biotechnology journal
Year: 2012, Volume: 7, Issue: 6, Pages: 779-788
ISSN:1860-7314
DOI:10.1002/biot.201100350
Online Access:Verlag, Volltext: http://dx.doi.org/10.1002/biot.201100350
Verlag, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/biot.201100350
Get full text
Author Notes:Van Thanh Hoang, Abraham Zepeda‐Moreno and Anthony D. Ho (Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany)
Description
Summary:Acute myeloid leukemia (AML) is considered to be a disease of stem cells. A rare defective stem cell population is purported to drive tumor growth. Similarly to their normal counterparts, leukemic stem cells (LSC) divide extreme slowly. This may explain the ineffectiveness of conventional chemotherapy in combatting this disease. Novel treatment strategies aimed at disrupting the binding of LSC to stem cell niches within the bone marrow might render the LSC vulnerable to chemotherapy and thus improving treatment outcome. This review focuses on the detection of LSC, our current knowledge about their cellular and molecular biology, and LSC interaction with the niche. Finally, we discuss the clinical relevance of LSC and prospective targeted treatment strategies for patients with AML.
Item Description:First published: 16 May 2012
Gesehen am 22.10.2018
Physical Description:Online Resource
ISSN:1860-7314
DOI:10.1002/biot.201100350